Zhang-JianXin

@AI_Jasonyu 那也算是个优势了。iPhone不用借助Android或写卡器。（大佬使用的时候是否有免费时限？在网页上没提到。）

@windlemna 这些卡都在不断迭代，Bootstrap可以用来下载，最早也是不行的，后面都是迭代支持了

@whyeszhu 这两年报结果的研究太多了，指南于是赶紧都更新上来。

@BenCreelan @BenjaminBesseMD Immunotherapy stops at 2 yrs in clinical trials. If discontinuation caused relapse, PFS should plummet after that — but it doesn't. This points more toward resistance than stopping treatment. No wonder rechallenge ORR isn't great.

High quality study from @BenjaminBesseMD showing only 26% of pts need retreatment after getting 2 yrs pembro for NSCLC. However, outcome for IO rechallenge was mixed, w/ many pts clearly not responding and dying. Much like CM-153 & w/ prior pooled report of Abreu-Rodriguez showing only 19-27% ORR with pembro re-challenge. So still an unresolved question: whether 2-yr discontinuation is optimal for all patients? @GustaveRoussy

@ArndtVogel @HEP_Journal Neoadjuvant ≠ Conversion therapy. The former aims to minimize the risk of progression (ORR is not important!) , while the latter pursues a greater depth of response.

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in BCLC A HCC and high risk of recurrence @HEP_Journal doi.org/10.1097/HEP.00… 🔎🇫🇷43 pts, NIVOLEP trial 👉ORR 25% after Nivo 👉2yrs OS rate 75% 🧐Not sure whether there is a future for IRI in HCC, but interesting data @EASLedu @myESMO @ILCAnews

@ChandrakanthMv Comparing concurrent vs. just the 1st step of sequential therapy is an unfair comparison. A positive PFS is no surprise, but it comes at the cost of losing a line of therapy for post-progression survival.

Cancer therapy is evolving even in intermediate-stage HCC. CARES-005 trial shows that combining TACE + PD-1 inhibitor + VEGFR inhibitor can significantly delay progression. • Median PFS: 10.8 vs 3.2 months • HR 0.34 Combination strategy may be the future. #MVOnco #HCC #Oncology

@OscarTahuahua Did they use a placebo control? Both groups should ideally have morning and afternoon infusions to rule out bias. It’s a low-cost measure that would effectively control for the psychological and lifestyle impact of the infusion time itself.

More evidence that #immunotherapy works better in the morning. In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC. More effective, no added cost and easy to implement. Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion. doi.org/10.1038/s41591… @OncoAlert

@DaisukeKotani @NatureMedicine Did they use a placebo control? Both groups should ideally have morning and afternoon infusions to rule out bias. It’s a low-cost measure that would effectively control for the psychological and lifestyle impact of the infusion time itself.

Early Time-of-Day (ToD) ICI Infusion Improves Outcomes? @NatureMedicine #ASCO25 ◾️rPh3 of early (before 15:00) vs late (after 15:00) immunochemotherapy for NSCLC ◾️PFS (HR 0.40) & OS (HR 0.42) significantly improved in early ToD group 👉First randomized trial confirming retro data. While mechanisms need further elucidation, it seems prudent to avoid evening ICI infusions when feasible. 🔗doi.org/10.1038/s41591… @OncoAlert

@NiuSanford RTOG 1112 started at 2013. CARES-310 started at 2019. IMbrave 150 result was published at 2020. RTOG 1112 was early terminated at 2021 because of slow enrollment.

Worth noting that RTOG 1112 (sorafenib +/- SBRT) was criticized heavily for using sorafenib as control arm. CARES-310 started enrollment 6 years later, also compared against sorafenib, but this has generated far less pushback.

@DrSwaroopOnco @ArndtVogel @TheLancetOncol The trial started at 2019, when sorafenib was the standard therapy.

@ArndtVogel @TheLancetOncol Why sorafenib as the control arm

🔥off the press🔥 Camrelizumab plus rivoceranib vs sorafenib as 1st line therapy for HCC @TheLancetOncol authors.elsevier.com/c/1m9sN5EIIgTS… 🔎CARES-310 final analysis 👉mOS: 23·8 vs 15·2 mo 👉mPFS: 5·6 vs 3·7 mo 🧐Many positive phase-2 and -3 study with this combo, form peri-operative to advanced @myESMO @EASLedu @ILCAnews

@DrRishabhOnco OK I've find it now. doi.org/10.1016/j.esmo…

@DrRishabhOnco I only find the preprint version: DOI:10.20944/preprints202511.0021.v1

🚨 GCD vs GCS in Advanced Biliary Tract Cancer - Real-World Head-to-Head! 🇯🇵 Durvalumab + GemCis (GCD) vs S-1 + GemCis (GCS) - the first real-world comparison, 265 pts, NCC Japan. 🔥 Key Results (n=265): 🟦 mOS: 17.1 mo (GCD) vs 18.3 mo (GCS) - NS 🟥 mPFS: 8.0 mo (GCD) vs 8.9 mo (GCS) - trend (P=0.077) 🟩 DoR: 12.7 mo (GCS) vs 7.5 mo (GCD) - Significantly longer 🟨 ORR: 28.9% vs 22% - similar 🟧 Grade ≥3 AEs: 66% (GCD) vs 49% (GCS) 🧬 Genomics: ARID1A MT, PIK3CA MT & SMAD4 WT → benefit with GCS 📌 Maintenance effect? • GCD → 8 cycles then durvalumab maintenance • GCS → continuous therapy beyond 16 cycles → May explain longer DoR with GCS. 💡 Takeaway Both regimens are valid standards in Asia, but GCS offers longer DoR, similar OS/PFS, fewer grade ≥3 toxicities, and dramatically lower cost. In selected genomics (ARID1A/PIK3CA/SMAD4 WT) → GCS may outperform GCD. 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #GastroOncology #BiliaryTractCancer @OncoAlert @myesmo @esmo_open @ASCO

@ArndtVogel @Cancer_Cell @grok Is this better than immuno-free therapy?

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in MSS BRAF V600E mCRC @Cancer_Cell doi.org/10.1016/j.ccel… 👉ORR 42%, mPFS 7.2 mo, mOS 22mo 👉Extracellular vesicle & tumor RNA profiling to identify immune signatures 🧐BRAF+EGFR+PD-1 shows some clinical efficacy > biomarker @myESMO

@whyeszhu 能持续更新数据的研究可以有更多启发。这个研究OS的HR果然也降了。

@radiology_rsna The two websites are same.

Diagnosis 3: pubs.rsna.org/doi/10.1148/ra… Diagnosis 6: pubs.rsna.org/doi/10.1148/ra…

#RadiologyMadness presented by #RadinTraining Region 3 First Round Matchup Diagnosis 3 vs Diagnosis 6 VOTE BELOW!

@whyeszhu 从禁忌证出发这个推荐的思路更加倾向于免疫治疗。不过单纯免疫治疗的PD率还是要高于单纯靶向的，所以除了禁忌证之外，还得考虑对于短期内病情进展的容受性。

@applelovecherr1 如果喜欢虾可考虑明月虾面（一家又小又旧的路边馆子）。 如果对蛋和肉有兴趣可以考虑灌蛋（一定程度上被视为收割游客的产品但是味道着实不错）。

闪现厦门，集美附近逛一逛和鼓浪屿也没什么区别嘛，石鼓路和租用的电动车yyds

@ivremort_ 哪怕是看完并且理解，也有很多医生是不敢这么干的，还得是专业。

@aliciahan007 这疗法的一个优点是：抗乙肝作用是它在主要目标（抗肿瘤治疗）之外的作用。另一个优点是：一次治疗，潜在持久获益。 但缺点也在于此：对于非肿瘤的人群来说，治疗风险可能过高了，对于研究人群之外的范围并不普适。

2025年了啊， 总想写点什么， 又不知道如何提笔。 突然看到有人聊起来了11月分AASLD有关TCR-T细胞疗法可能持久性的治愈方案， 不如就从这里开始聊聊。 中国毕竟是乙肝大国， 身边很多亲戚朋友是携带者。 我把翻译放图2. 小红书很多人宣称这是治愈， 我倒是不觉得， 因为虽然很乐观，但是首先也就观察了1年， 其次它只看HBsAg水平， 而其他hbv-dna什么的同样重要。 但是， 越来越多的科技啊， 医疗上面的各种突破性进展， 让我突然觉得有一天哪个AI论坛上有个人说的话可能真的要实现了： “5-10年内， 可能所有现在已知的疾病都有可能治愈。包括癌症。” 其实， 很多时候我们极有可能生活在一个时代的转折点。 但是本身却不自知。 且不如多给生活一些美好的期待吧。 2025祝大家身体康健， 幸福顺意。

@hsn8086 o1也不行（和前面GPT4o的回答差不多），给了提示之后不但跟上了，还产生了新的解读……